Prana Biotechnology Ltd (PRAN) 1.85 $PRAN
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...
This Week in Biotech: Data Disappointments Come in Threes
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 05, 1:15PM CDT
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.
Why Prana Biotechnology (PRAN) Stock Is Down Today
at The Street - Tue Apr 01, 9:13AM CDT
Prana Biotechnology (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed. The experimental drug did not reach the study's main endpoint of a statistically significant...
Downgrade Alert for Prana Biotechnology (PRAN)
Comtex SmarTrend(R) - Tue Apr 01, 7:03AM CDT
Prana Biotechnology (NASDAQ
RAN) was downgraded from Buy to Neutral at H.C. Wainwright today. The stock closed yesterday at $2.80 on volume of 23.6 million shares, above average daily volume of 2.9 million. In the past 52 weeks, shares of Prana Biotechnology have traded between a low of $2.12 and a high of $13.29 and closed yesterday at $2.80, which is 32% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.3% while the 50-day MA has advanced 0.6%.
Coca-Cola Falls as Soda Sales Drop for 9th Straight Year
ACCESSWIRE - Tue Apr 01, 12:59AM CDT
Bank of America Corporation (NYSE: BAC) - For an in-depth report on Bank of America Corporation follow: www.BullTrends.com/stockquote/BAC
Investor Beat: The End of the First Quarter -- How Did We Do?
Chris Hill, The Motley Fool - Motley Fool - Mon Mar 31, 6:50PM CDT
The first quarter of 2014 officially wrapped up today, and though the Dow, Nasdaq and S&P were all up today, the quarter itself was the worst since the end of 2012. Are stocks finally pulling back enough for investors to find value on the market...
Big Movers Today: Panera, Delta, GM, and Prana Biotechnology
Chris Hill, The Motley Fool - Motley Fool - Mon Mar 31, 6:34PM CDT
Shares of Panera Bread moved upward today, after the stock got an analyst upgrade from Wedbush. Delta Airlines stock is also on the rise, after announcing a partnership with Virgin Atlantic. Shares of General Motors fell today in advance of...
Down 70%: Is Prana Biotechnology Ltd. a Buy?
David Williamson, The Motley Fool - Motley Fool - Mon Mar 31, 6:03PM CDT
The biggest loser today in the biotech space was Prana Biotechnology , down a massive 70% because its candidate Alzheimer's drug PBT2 failed its phase 2 trial. The drug failed not only to improve cognitive function, but it also failed to affect...
Lions Gate and Prana are big market movers
By The Associated Press - AP - Mon Mar 31, 3:57PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Prana Biotechnology Limited Got Pummeled
Brian Pacampara, The Motley Fool - Motley Fool - Mon Mar 31, 1:22PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Prana Biotechnology Limited plummeted 70%...
Hot Stock: Prana Biotechnology, Shares Drop 70.4% (PRAN)
Comtex SmarTrend(R) - Mon Mar 31, 10:11AM CDT
Prana Biotechnology (NASDAQRAN) is one of today's worst performing low-priced stocks, down 70.4% to $2.92 on 5.3x average daily volume. Thus far today, Prana Biotechnology has traded 15.5 million shares, vs. average volume of 2.9 million shares per day. The stock has underperformed the Dow (-70.4% to the Dow's 0.7%) and underperformed the S&P 500 (-70.4% to the S&P's 0.8%) during today's trading.
Ahead of the Bell: Prana Biotechnology shares skid
By The Associated Press - AP - Mon Mar 31, 8:00AM CDT
Shares of Prana Biotechnology Ltd. shed most of their value Monday before markets opened and after the Australian drug developer said its most advanced potential treatment missed the main goal in a study of patients with Alzheimer's disease.
Prana Biotechnology announces preliminary results of Phase 2 IMAGINE trial of PBT2 in Alzheimer's disease
PR Newswire - Mon Mar 31, 6:05AM CDT
Prana Biotechnology (ASXBT/NASDAQRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.
Prana Alzheimer's Study Fails
at The Street - Mon Mar 31, 5:54AM CDT
The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
3 Biotechs Expecting Data
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 3:09PM CDT
The release of clinical trial data can be make-or-break moments for biotech companies. Three companies, Exelixis , Vertex Pharmaceuticals , and Prana Biotechnology are finishing up trials, and should release data shortly. Exelixis' trials,...
Huntington's Reviewed by NeuroPerspective
PR Newswire - Tue Mar 04, 7:30AM CST
NI Research has released the March issue of NeuroPerspective, which reviews and assesses the range of neurotherapeutics programs in development for Huntington's Disease. Huntington's is a devastating orphan neurodegenerative disorder known to affect approximately 30,000 patients in the United States, with another 150-200,000 individuals genetically at risk for the disease. Recent weeks have seen the release of Phase II trial results in HD from both Prana Biotechnology and Raptor Pharmaceuticals, those results catalyzing fresh interest in this area.
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...
This Week in Biotech: Data Disappointments Come in Threes
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 05, 1:15PM CDT
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.
Why Prana Biotechnology (PRAN) Stock Is Down Today
at The Street - Tue Apr 01, 9:13AM CDT
Prana Biotechnology (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed. The experimental drug did not reach the study's main endpoint of a statistically significant...
Downgrade Alert for Prana Biotechnology (PRAN)
Comtex SmarTrend(R) - Tue Apr 01, 7:03AM CDT
Prana Biotechnology (NASDAQ
RAN) was downgraded from Buy to Neutral at H.C. Wainwright today. The stock closed yesterday at $2.80 on volume of 23.6 million shares, above average daily volume of 2.9 million. In the past 52 weeks, shares of Prana Biotechnology have traded between a low of $2.12 and a high of $13.29 and closed yesterday at $2.80, which is 32% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.3% while the 50-day MA has advanced 0.6%. Coca-Cola Falls as Soda Sales Drop for 9th Straight Year
ACCESSWIRE - Tue Apr 01, 12:59AM CDT
Bank of America Corporation (NYSE: BAC) - For an in-depth report on Bank of America Corporation follow: www.BullTrends.com/stockquote/BAC
Investor Beat: The End of the First Quarter -- How Did We Do?
Chris Hill, The Motley Fool - Motley Fool - Mon Mar 31, 6:50PM CDT
The first quarter of 2014 officially wrapped up today, and though the Dow, Nasdaq and S&P were all up today, the quarter itself was the worst since the end of 2012. Are stocks finally pulling back enough for investors to find value on the market...
Big Movers Today: Panera, Delta, GM, and Prana Biotechnology
Chris Hill, The Motley Fool - Motley Fool - Mon Mar 31, 6:34PM CDT
Shares of Panera Bread moved upward today, after the stock got an analyst upgrade from Wedbush. Delta Airlines stock is also on the rise, after announcing a partnership with Virgin Atlantic. Shares of General Motors fell today in advance of...
Down 70%: Is Prana Biotechnology Ltd. a Buy?
David Williamson, The Motley Fool - Motley Fool - Mon Mar 31, 6:03PM CDT
The biggest loser today in the biotech space was Prana Biotechnology , down a massive 70% because its candidate Alzheimer's drug PBT2 failed its phase 2 trial. The drug failed not only to improve cognitive function, but it also failed to affect...
Lions Gate and Prana are big market movers
By The Associated Press - AP - Mon Mar 31, 3:57PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Prana Biotechnology Limited Got Pummeled
Brian Pacampara, The Motley Fool - Motley Fool - Mon Mar 31, 1:22PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Prana Biotechnology Limited plummeted 70%...
Hot Stock: Prana Biotechnology, Shares Drop 70.4% (PRAN)
Comtex SmarTrend(R) - Mon Mar 31, 10:11AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's worst performing low-priced stocks, down 70.4% to $2.92 on 5.3x average daily volume. Thus far today, Prana Biotechnology has traded 15.5 million shares, vs. average volume of 2.9 million shares per day. The stock has underperformed the Dow (-70.4% to the Dow's 0.7%) and underperformed the S&P 500 (-70.4% to the S&P's 0.8%) during today's trading. Ahead of the Bell: Prana Biotechnology shares skid
By The Associated Press - AP - Mon Mar 31, 8:00AM CDT
Shares of Prana Biotechnology Ltd. shed most of their value Monday before markets opened and after the Australian drug developer said its most advanced potential treatment missed the main goal in a study of patients with Alzheimer's disease.
Prana Biotechnology announces preliminary results of Phase 2 IMAGINE trial of PBT2 in Alzheimer's disease
PR Newswire - Mon Mar 31, 6:05AM CDT
Prana Biotechnology (ASX
BT/NASDAQRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. Prana Alzheimer's Study Fails
at The Street - Mon Mar 31, 5:54AM CDT
The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
3 Biotechs Expecting Data
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 3:09PM CDT
The release of clinical trial data can be make-or-break moments for biotech companies. Three companies, Exelixis , Vertex Pharmaceuticals , and Prana Biotechnology are finishing up trials, and should release data shortly. Exelixis' trials,...
Huntington's Reviewed by NeuroPerspective
PR Newswire - Tue Mar 04, 7:30AM CST
NI Research has released the March issue of NeuroPerspective, which reviews and assesses the range of neurotherapeutics programs in development for Huntington's Disease. Huntington's is a devastating orphan neurodegenerative disorder known to affect approximately 30,000 patients in the United States, with another 150-200,000 individuals genetically at risk for the disease. Recent weeks have seen the release of Phase II trial results in HD from both Prana Biotechnology and Raptor Pharmaceuticals, those results catalyzing fresh interest in this area.
